- New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha (“efti” or “IMP321”) as part of a cancer peptide vaccine discovered by artificial intelligence
- Builds on Immutep’s longstanding relationship with CYTLIMIC, which recently reported encouraging data in a Phase I clinical trial with their cancer vaccine product candidate including efti
SYDNEY, AUSTRALIA – 7 January 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep” or “the Company”), is pleased to announce that it has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. (the “Agreements”) for its lead product candidate eftilagimod alpha as part of a cancer vaccine.
For further information please download PDF attached:
Download this document